Serologicals has named Wylie Chenn as regional director for the Asia/Pacific region, the company said last week.
Chenn was most recently general manager, bioscience division for the Asia/Pacific region for Fisher Scientific. He received a BS in marketing and international business from Brigham Young University and an MBA from the University of Washington.
Invitrogen President and CEO Greg Lucier has become a member of the board of trustees of the Burnham Institute, the La Jolla, Calif.-based institute said last week.
Qiagen last week announced the launch of its Human Druggable Genome siRNA Set V2.0. It made the first delivery of the product to the Scripps Research Institute in Florida.
The new Druggable Genome Set enables gene silencing studies of 6,692 potential human druggable targets, Qiagen said. The siRNAs are designed using Qiagen's HiPerformance siRNA Design Algorithm, which ensures maximum silencing and minimum risk of non-specific events, Qiagen said.